|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Departments of Medicine (Hematology/Oncology)
and Pathology, Westfaelische Wilhelms Universitaet Muenster; the
Department of Pathology, Freie Universitaet Berlin; and the Department
of Hematology and Oncology, University Hospital Koeln, Germany.
Tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 are
proteins with proteinase-inhibiting and cytokine properties. TIMP-1 is
active primarily in B cells and B-cell lymphomas, whereas TIMP-2
expression is restricted to T cells. The expression of TIMP-1 and
TIMP-2 in lymph nodes from patients with Hodgkin disease (HD) and in
Hodgkin-derived cell lines was investigated. In situ hybridization showed TIMP-1 RNA expression in 3% to 80% of
Hodgkin/Reed-Sternberg (H/R-S) cells from 14 of 15 patients, with
results in one patient being at the lowest detection limit; no
expression of TIMP-2 in H/R-S cells; and only weak expression of TIMP-2
in reactive lymphoid tissue. Production of TIMP-1 protein by H/R-S
cells was accordingly found on immunohistochemical analysis of lymph
nodes from patients with HD. There was only low expression of matrix
metalloproteinase (MMP)-2, which is mainly inhibited by TIMP-2; no
expression of MMP-1 and MMP-3 in reactive lymphoid tissue; and no
expression of these MMPs in H/R-S cells. Thus, TIMP-1 expression in
lymph nodes was not correlated with metalloproteinase expression. Five of 7 Hodgkin-derived cell lines expressed TIMP-1 at the protein level.
Only one of these cell lines expressed TIMP-2, at the lowest detection
limit. TIMP-1 levels in plasma from patients with HD were within the
same range as those in plasma from healthy controls. Recombinant human
TIMP-1 inhibited induced cell death in Hodgkin-derived cell lines in
vitro. TIMP-1 and TIMP-2 inhibited T-cell cytotoxicity against
autologous cells presenting tumor-associated antigens and in allogeneic
mixed lymphocyte cultures. Thus, TIMP-1, aside from its role in
proteinase equilibrium, is an autocrine and paracrine survival factor
for H/R-S cells and an immunosuppressive protein expressed in Hodgkin lymphomas.
(Blood. 2002;99:258-267) Hodgkin disease (HD) comprises a lymphoma
entity1 and has different histological subtypes. Cytokines
play a major role in HD.2-5 Some cytokines are thought to
produce symptoms such as fever, night sweats, and weight loss, and some
have been described as autocrine or paracrine growth factors. The
histopathological presentation of the HD subtypes of nodular sclerosis
(NS) and mixed cellularity (MC) is characterized by a few neoplastic
Hodgkin/Reed-Sternberg (H/R-S) cells and an abundant infiltration with
immune cells, eosinophils, histiocytes, stroma cells, and extracellular
matrix (ECM). These features are thought to be related partly to
cytokines such as interleukin-1 (IL-1), IL-5, IL-7, IL-8,
lymphotoxin- Remodeling of ECM is important during normal development and under
pathologic conditions. The matrix metalloproteinases (MMPs) are a
family of zinc-dependent peptidases, including collagenases, gelatinases, and stromelysins, that degrade components of ECM and thus
play a role in tissue remodeling as well as morphogenesis, angiogenesis, tissue repair, and particularly, tumor
invasion.11-18 Most MMPs are secreted as zymogen and
activated by other proteases. The activities of MMPs are regulated by a
family of specific inhibitors called tissue inhibitors of
metalloproteinases (TIMPs). Four TIMPs have been cloned:
TIMP-1,19 TIMP-2,20 TIMP-3,21-24
and TIMP-4.25 The structural properties of some TIMPs have
been studied in detail,26,27 as has their mechanism of MMP
inhibition by complex formation.28 A balance between MMPs
and TIMPs is physiologically important, and TIMP levels are regulated
by steroids, growth factors, and cytokines such as IL-1, IL-6, IL-10,
leukemia inhibitory factor, ciliary neurotrophic factor, oncostatin M,
TNF- Only a few studies of the expression and function of TIMPs in lymphoid
cells or lymphoma have been described and none investigated HD.
Trafficking of lymphocytes is controlled by the balance between MMPs
and TIMPs, both of which are produced by these cells.37,38 TIMP-1 expression is elevated in patients with malignant non-Hodgkin lymphoma (NHL) and correlates with clinical aggressiveness of the
disease.39 TIMP-1 expression in NHL is regulated by
IL-6.40 Interestingly, TIMP-1 expression was reported to
be restricted to the B-cell lineage and TIMP-2 expression to the T-cell
lineage.41 In accordance with results of studies reporting
on cytokinelike activities of TIMPs in a wide variety of cell
types,32,42-48 Guedez et al observed that TIMP-1 was
a survival factor for B cells and induced differentiation in such
cells.49-50
To understand further the role of TIMPs in the NS compared with the MC
subtype of HD, we studied expression of some members of the MMP and
TIMP families in HD. Furthermore, we tested TIMP function in the
proliferation and survival of H/R-S cells in vitro and in allogeneic
mixed lymphocyte cultures (MLC) and autologous antitumor T-cell
cytotoxicity in vitro. Our results show that the proteinase inhibitor
TIMP-1 is an autocrine and paracrine survival factor that inhibits
induced cell death in H/R-S cells. Surprisingly, we also found TIMP-1
to be an immunosuppressive molecule expressed by HD lymphoma cells in
situ and in vitro.
Patients
Heparin-treated plasma from 46 patients with HD treated in studies of
the German Hodgkin Lymphoma Study Group was obtained either while
active disease was present (DP) or during complete remission (CR; NS or
MC subtype; no further selection), stored frozen, and used in
enzyme-linked immunosorbent assay (ELISA) analysis. Control plasma was
obtained from healthy volunteers.
Cells
In situ hybridization TIMP-1 and TIMP-2 gene probes were generated by oligo(dt)-primed reverse transcription of total-cell RNA prepared from human placentas and HT144 melanoma cells (HTB 63; ATCC), respectively, with subsequent amplification using specific oligodeoxyribonucleotide primers. Primers for TIMP-1 corresponded to nucleotides 69 to 116 and 645 to 665 and those for TIMP-2 to nucleotides 490 to 514 and 981 to 1001 of the published sequences.19,20,52 Sequence analysis was done to verify authenticity of the amplification products. After linearization of plasmids (pAMP1; Gibco BRL) containing specific sequences of the genes for TIMP-1 and TIMP-2, sulfur 35-labeled run-off antisense and sense (control) transcripts were generated by using Sp6 and T7 RNA polymerases (Gibco BRL). MMP-1, MMP-2, and MMP-3 gene probes were obtained and used as described previously.53,54 ISH for detection of RNA transcripts was done as described previously.55 Briefly, dewaxed and rehydrated paraffin sections were exposed to 0.2 N hydrochloric acid (HCl) and 0.125 mg/mL pronase (Boehringer Mannheim, Germany). This was followed by acetylation with 0.1 M triethanolamine (pH 8.0) and 0.25% (vol/vol) acetic anhydride and dehydration through graded ethanols. Slides were hybridized to a level of 2 to 4 × 105 cpm of labeled probes overnight at 54°C. Washing and autoradiography was done as described previously.56All sections were processed in parallel by using the same batches of reagents and probes. Incubation of sections with Micrococcus nuclease (Boehringer Mannheim) before ISH resulted in extinction of the specific autoradiographic signal, thereby establishing that RNA sequences were the targets of the hybridization procedure.57 ISH results were quantitated by directly visualizing and assessing the percentage of positive H/R-S cells, with results verified by a second person. Immunohistochemical analyses TIMP-1-specific immunoreactivity was assessed by using a human TIMP-1-specific monoclonal antibody (mAb; clone 147-6D11; Oncogene, Boston, MA) on acetone-fixed frozen sections, and CD30 staining was done in adjacent serial sections with the mAb Ber-H2 (Dako, Hamburg, Germany). The TIMP-1-specific antibody was also used in a 1:30 dilution for immunostaining of HD-derived cell lines after cytocentrifugation and fixation in acetone. Immunostaining was developed by the alkaline phosphatase antialkaline phosphatase (APAAP) method using new fuchsin as the chromogen.ELISA analysis TIMP levels in plasma and cell-culture supernatants were measured by using ELISA kits (R&D Systems, Wiesbaden, Germany) as described by the manufacturer. Plasma (stored at 80°C) was measured either directly or after additional dilution. Cells from cell lines
were washed and cultured at a concentration of 106 cells/20
mL of AIM V medium for 48 hours (pH 7.2, 37°C, 5% carbon dioxide
[CO2], and high humidity). Subsequently, culture
supernatants were harvested, stored at 80°C, and either used
directly for ELISA or assayed after additional dilution.
Cell-proliferation assays Cell lines derived from H/R-S cells were assayed for proliferation in the presence of recombinant human (rh) TIMP-1, rhTIMP-2 (Oncogene Products, Calbiochem-Novabiochem, Bad Soden, Germany), and TIMP-1 mAb (clone 7-6C1, Oncogene) by using tritium-thymidine uptake as a read-out. For the tritium-thymidine-uptake assay, 6.6-µL aliquots of rhTIMP-1 or of anti-TIMP-1 antibody and bovine serum albumin (BSA) in AIM V medium were seeded into 6 wells/test group of 96-well flat-bottomed microtiter plates (NUNC, Kamstrup, Denmark) at various concentrations. The wells already contained 200 µL of the cell suspension (1 × 104 cells/well). Controls contained 6.6 µL phosphate-buffered saline with 0.1% BSA vehicle without TIMP or antibody. The values reported are the final TIMP or antibody concentrations. Plates were incubated at 37°C (pH 7.2) in an atmosphere of 5% CO2 and high humidity for up to 48 hours. The cultures were pulsed for the last 6 hours with 0.25 µCi (0.00925 MBq) tritium-thymidine per well (specific activity, 21.0 mCi/mg [777MBq/mg]; Amersham Pharmacia Biotech Europe, Freiburg, Germany). The samples were then processed and counted (Trilux liquid scintillation and luminescence counter [1450 Microbeta]; Wallac Distribution, Freiburg, Germany). The values reported are means ± SD.MLC and chromium 51-release assay MLC were established essentially as described previously.58,59 Briefly, blood was drawn from histoincompatible healthy donors (stimulator and responder) and subjected to Ficoll treatment, and the interphase cells were washed twice. Stimulator mononuclear cells were irradiated (30 Gy). In one experiment, stimulation was done with CD14-enriched cells (by using a magnetically activated cell sorter and CD14 microbeads; Miltenyi Biotech, Bergisch-Gladbach, Germany) and irradiated cells. Irradiated stimulator cells (8 × 106) and viable responder cells (2 × 107) were coincubated (pH 7.2, 37°C, 5% CO2, and high humidity) for 5 days in aliquots of 15 mL RPMI 1640 medium supplemented with 2 mM glutamine and 10% FCS in 50-mL Falcon tubes with repeated, gentle agitation (once a day). On the fifth day, fresh, nonirradiated stimulator cells (obtained as described above; 2 × 106 cells/100 µL) were labeled for 90 to 120 minutes (pH 7.2, 37°C, 5% CO2, and high humidity) with 100 µCi (3.6 MBq) sodium chromium 51 (51Cr)-chromate (100-µL volume; specific activity; 471.2 mCi/mg [17435.1 MBq/mg]; Amersham). Labeled cells were washed 3 times in 1640 RPMI medium with 10% FCS. Meanwhile, effector cells were preincubated with rhTIMP-1 or rhTIMP-2 in various concentrations or with control vehicle for 3 hours. Subsequently, each V-shaped bottom well of the 96-well microtiter plates received a total volume of 150 µL labeled stimulator/target cells and responder/effector cells in the selected effector-to-target ratios, with either rhTIMP-1 or rhTIMP-2 in the concentrations indicated or control vehicle. Microplates were then incubated for 4 hours (pH 7.2, 37°C, 5% CO2, and high humidity) and centrifuged for 5 minutes at 200g. Aliquots of the supernatants were assayed for radioactivity. Maximum Cr release was assayed after Triton X-100 treatment of the wells. Spontaneous chromium (Cr) release from target cells was assayed in medium only. Mean results from triplicates were expressed as the percentage of specific Cr release (experimental Cr release [in cpm] minus spontaneous Cr release [in cpm] times 100 divided by maximum Cr release [in cpm] minus spontaneous release).Autologous antitumor T-cell cytotoxicity In one experiment, we used autologous (HLA-A2-positive) phytohemagglutinin-stimulated lymphocytes pulsed with a melanoma-associated nonapeptide (Ile-Met-Asp-Gln-Val-Pro-Phe-Ser-Val, a gp100 peptide modified in position 2 to yield a higher affinity for HLA-A*0201-binding anchor sites than the native peptide60) as a stimulator/target cell and lymphocytes (after 3 periods of stimulation by nonapeptide-presenting cells [autologous to the effector lymphocytes]) as responder/effector cells; other variables were as described above for the MLC.Apoptosis assays Annexin V and propidium iodide staining and DNA fragmentation studies with fluorescence-activated cell-sorter scanning analysis. To assay the influence of rhTIMP-1 on radiation-induced apoptosis of cell lines derived from H/R-S cells, 1 × 106 cells/mL were incubated (37°C, pH 7.2, 5% CO2, and high humidity) with either 500 ng/mL rhTIMP-1 or control medium without TIMP-1, subsequently irradiated (30-90 Gy), and subjected to FACS analysis for annexin V and propidium iodide (PI) staining after additional incubation periods of 4, 12, and 24 hours. Apoptosis was assayed by annexin V, and PI staining (Becton Dickinson, Mountain View, CA) was done to identify apoptotic and dead cells. The cell suspension was kept at 4°C in the dark for 1 hour. The cell samples were then measured by using fluorescence-activated cell-sorter scanning (FACS) analyzer (FACS Calibur; Becton Dickinson) and analyzed with CellQuest and Paint-A-Gate 3.0 software on a Macintosh PC. To assay DNA fragmentation under the same conditions, degraded chromatin was detected by using terminal deoxynucleotidyltransferase deoxyuridine triphosphate nick-end labeling (TUNEL) with the APO-BRDU kit (Pharmingen, San Diego, CA), according to the manufacturer's instructions. Tritium-thymidine DNA fragmentation assay. The method used in these experiments was adapted from a protocol described by Brown and Phipps.61 Briefly, 2 × 107 Hodgkin cells (cell line L591) were labeled with 10 µCi tritium-thymidine in a total volume of 20 mL AIM V, 10% FCS, and 2% glutamine for 3.5 hours at 37°C. Cells were then washed twice and resuspended in a concentration of 150 × 103 cells/200 µL in AIM V, 10% FCS, and 2% glutamine. Subsequently, cells were incubated with or without 500 ng rhTIMP-1/mL for 1 hour before addition of 500 µM hydrogen peroxide (H2O2) or irradiation (90 Gy) for induction of apoptosis and cell death. Forty-eight hours after this treatment, cells were centrifuged and the supernatant was retained. The cell pellet was resuspended in 0.5 mL lysis buffer containing 5 mM Tris-HCl (pH 8.0), 20 mM EDTA [pH 8.0] and 0.5% Triton X-100. The lysate was centrifuged at 12 000g, and the supernatant was retained. The cell pellet was harvested on a filter mat (Wallac Distribution). The samples were then processed and counted (Trilux liquid scintillation and luminescence counter [1450 Microbeta]). The percentage of DNA fragmentation was calculated as the cpm for fragmentation for the reagent minus the cpm for fragmentation for the control, divided by the total cpm minus the cpm for fragmentation of the control, where the cpm for fragmentation was the cpm in the culture supernatant plus the cpm in the 12 000g supernatant, and the total cpm was the cpm for fragmentation plus the cpm in the 12 000g pellet. Statistical analysis Results were evaluated by using the Mann-Whitney test. P values lower than .05 were considered to represent a significant difference.
TIMP-1 RNA expression in sections of lymph node tissue from patients with the NS and MC subtypes of HD In a set of experiments using paraffin-embedded lymph node tissue sections from 8 patients with the NS subtype of HD and 7 patients with the MC subtype, we conducted assays for RNA expression of TIMP-1. TIMP-1 expression was detected in the samples from 14 of the 15 patients; in one additional sample, expression at the lowest detection limit was observed (Figure 1A and B and Figure 2). In every sample in which expression was observed, the H/R-S cells showed expression of TIMP-1. However, among these cases, various percentages between 3% and
80%of H/R-S cells were positive (Figure 2). Although there was a
trend toward a higher percentage of H/R-S cells expressing TIMP-1 in
samples from patients with the MC subtype, there was no significant
difference in TIMP-1 expression between the NS and MS histological
subtypes (Figure 2). Distinct, though light, positive signals were also
detected in reactive lymphoid tissue distributed throughout the lymph
nodes from all patients (both HD subtypes; Figure 1). These signals were most pronounced in areas of active tissue remodeling (Figure 1C).
TIMP-2 RNA expression in sections of lymph node tissue from patients with the NS and MC subtypes of HD Weak expression of TIMP-2 RNA was observed in all samples examined. In contrast to the results for TIMP-1, H/R-S cells were negative for TIMP-2 RNA (Figure 3A). On the other hand, reactive lymphoid tissue showed faint expression of TIMP-2 in some areas of tissue remodeling (Figure 3B). There was clear expression in fibrotic areas and lymph node capsules (Figure 3C).
MMP-1, MMP-2, and MMP-3 RNA expression in sections of lymph node tissue from patients with the NS and MC subtypes of HD There was only low expression of MMP-2, which is mainly inhibited by TIMP-2, in reactive lymphoid tissue, and no expression of MMP-2 in H/R-S cells. Furthermore, we observed no expression of MMP-1 or MMP-3 in H/R-S cells or reactive lymphoid tissue (data not shown). Thus, TIMP-1 expression in the lymph nodes was not correlated with expression of these MMPs.Presence of TIMP-1 protein in sections of lymph node tissue from patients with HD To assay lymph nodes of patients with HD for the presence of TIMP-1 protein, we used the APAAP technique to conduct immunohistochemical studies using specific antibodies against TIMP-1. Because we could not find TIMP-1 antibodies that were useful in studies in paraffin-embedded tissues, we tested 13 snap-frozen HD tissue samples. The antibody produced a diffuse background staining in 11 of 13 samples, with enhanced reactivity on a proportion of plasma cells and cell clusters comprising mononuclear cells, spindle-shaped cells, and a few H/R-S cells, as verified by colocalized CD30 reactivity in serial sections. In 2 samples, one each of the NS and the MC subtype, stored for shorter periods at80°C, background staining
was reduced, and a distinct specific, primarily cytoplasmic staining
was observed in cell clusters containing H/R-S cells (Figure
4). To check the validity of the
immunohistochemical analysis, we also tested our cell lines with this
technique (see below).
TIMP-1 and TIMP-2 levels in cell lines derived from H/R-S cells Next, we used ELISA to analyze TIMP-1 and TIMP-2 levels in supernatants of 7 cell lines derived from H/R-S cells. Supernatants of 5 of the 7 cell lines examined showed TIMP-1 protein in various concentrations (Figure 5). For 2 of those 5 cell lines, TIMP-1 levels were about 50 ng/mL. These experiments were reproduced twice, with similar results: the SD was less than 10%. In these experiments, we used as controls the K562 myeloid cell line, which is known to produce TIMP-1, and the Jurkat T-cell line, which is known to be negative for TIMP-1.41 Interestingly, when the serum in the growth conditions for the H/R-S-derived cell lines was reduced, cell supernatants of some cell lines showed considerably more TIMP-1 production on ELISA than those with growth conditions that included serum (the percentage increment in the absence of serum was 20% for the KMH2 cell line, 55% for the Holden line, and 77% for the HDLM2 line).
To check the validity of the immunohistochemical results, we also tested cell lines with different TIMP-1 production by ELISA using cytospin preparations for identical APAAP staining. In a blinded assay, a pathologist found that semiquantitative TIMP-1 staining strength directly correlated with TMP-1 levels on ELISA analysis (data not shown). Furthermore, when stained with the TIMP-1-specific mAb, cytospin preparations of cell lines produced slightly stronger staining of the cytoplasm when the cell lines underwent serum starvation before harvesting (data not shown). In contrast, none of the cell lines produced detectable amounts of TIMP-2 (data not shown). TIMP-1 levels in plasma from patients with HD and healthy controls on ELISA analysis Next, we assayed serum samples from 46 HD patients with either DP (n = 18) or CR (n = 28) for the presence of TIMP-1 protein. As shown in Figure 6, TIMP-1 was present in various amounts in plasma from all patients (both histological subtypes). In patients with DP, there was a trend toward higher TIMP-1 levels compared with those in controls and those in patients with CR; however, the differences were not significant (Figure 6).
Cell proliferation under the influence of rhTIMP-1 and antibody against TIMP-1 We found that TIMP-1 and not TIMP-2 was the TIMP expressed and secreted by H/R-S cells. Furthermore, there was no correlation between expression of TIMP-1 and MMP-1, MMP-2, and MMP-3. Therefore, we tested the hypothesis that TIMP-1 is an autocrine and paracrine growth factor in vitro for cell lines derived for H/R-S cells. We assayed tritium-thymidine uptake in these cell lines with and without the presence of either rhTIMP-1 or antibody against TIMP-1. We found that neither rhTIMP-1 nor the TIMP-1 antibody had a significant effect on cell proliferation (Table 1).
Induced apoptosis of H/R-S cells in the presence of rhTIMP-1 Because the higher production of TIMP-1 in the absence of serum indicated a stress-induced production of this molecule by the H/R-S-derived cell lines, we tested the influence of rhTIMP-1 on induced cell death in those cell lines. We found that induction of a high percentage of apoptosis in the cell lines by radiation required comparatively high doses of radiation. For the first series of experiments, the cell lines were incubated with or without rhTIMP-1 (500 ng/mL) for 15 minutes, irradiated (60-90 Gy), incubated for 4 to 24 hours, and subjected to annexin V and PI FACS analysis. We found that rhTIMP-1 inhibited or retarded radiation-induced apoptosis and diminished the numbers of dead cells in all the Hodgkin-derived cell lines in which increased annexin V and PI staining was induced by radiation (Figure 7). The death of radiation-resistant cell lines was less influenced by rhTIMP-1.
These results were confirmed in a subsequent series of experiments
using detection of specific chromatin degradation by either nick end
labeling with dUTP and by anti-BRDU FACS analysis or detection of
tritium-thymidine-labeled DNA fragments in the supernatant and
cytoplasm of apoptotic cells (Figure 8).
In the DNA fragmentation assay, we also used
H2O2 to induce apoptosis and cell death. As shown in Figure 8, rhTIMP-1 reduced
H2O2-induced cell death. However, rather high
concentrations of H2O2 were necessary because
of the comparatively high resistance to apoptosis of the cell lines. With all 3 assessment methods used, inhibition of radiation-induced or
H2O2-induced apoptosis by TIMP-1 was not
complete but showed considerable variability (Figures 7 and 8).
Studies of the role of TIMP-1 as a candidate molecule for escape from the immune response in HD To investigate further the putative role of TIMP-1 in the mechanisms by which H/R-S cells can escape an effective immune response, we studied the effect of rhTIMP-1 and rhTIMP-2 on T-cell-mediated cytotoxicity in alloreactive MLC and antitumor T-cell cytotoxicity as in vitro model systems. In different sets of experiments, both rhTIMP-1 and rhTIMP-2 inhibited T-cell-mediated cytotoxicity against different target cells after only a few hours in the cultures (Figure 9). This effect was most pronounced at higher effector-to-target ratios; in several experiments, there was almost complete suppression of cytotoxicity by both TIMP molecules (Figure 9). However, inhibition of T-cell cytotoxicity by both TIMP molecules varied considerably among different experiments using different cell donors (Figure 9). At optimal effector-to-target ratios, there was a 20% to 90% inhibition of T-cell cytotoxicity by rhTIMP-1 throughout the complete series of experiments.
For this investigation, we originally hypothesized that RNA expression of MMPs and TIMPs would be different in samples from patients with the NS subtype of HD than in those from patients with the MC subtype and that this would help explain the development of fibrotic tissue in NS. However, we found no significant difference in RNA expression between the 2 histological subtypes. In particular, expression of TIMP-1 was independent of the histological type of disease (Figures 1 and 2). Thus, the primary biologic function of TIMP-1 in HD is not to influence ECM composition by changing matrix degradation. We found expression of TIMP-1 RNA in all lymph node sections from patients with HD, regardless of whether they had the NS or the MC subtype (Figure 1 and 2). Expression was mainly in H/R-S cells. At the protein level, TIMP-1 immunoreactivity was diffusely distributed in most cases. However, in some cases in which there was a shorter period of storage of frozen material, staining was accentuated around clusters of cells containing H/R-S cells. These results were verified by CD30 staining on adjacent serial sections, indicating that TIMP-1 is translated and secreted by H/R-S cells (Figure 4). In contrast, TIMP-2 expression was essentially absent from H/R-S cells and present only in reactive lymphoid tissue (Figure 3). Furthermore, ELISA analyses detected TIMP-1 in supernatants of most of the H/R-S-derived cell lines (Figure 5), whereas TIMP-2 was again essentially absent. These findings were not paralleled by considerable expression of MMP, and there was no significant difference between the NS and MC subtypes in the expression level when different amounts of ECM were present in the lesion. Additionally, TIMP-1 protein was detected by ELISA in plasma from patients with HD (Figure 6). However, levels were in the same range as those in healthy controls. This may be explained by the fact that H/R-S cells constitute only a minority of nucleated cells in Hodgkin lesions and that only proportions of H/R-S cells expressed TIMP-1 at notable levels. Only a few studies of the expression and function of TIMPs in lymphoma have been reported, and none investigated HD. TIMP-1 is expressed at elevated levels in patients with malignant NHL, and such expression correlates with the clinical aggressiveness of the disease.39 In NHL, expression of TIMP-1 is regulated by cytokines such as IL-6.40 Interestingly, TIMP-1 expression was found to be restricted to the B-cell lineage and, only at low levels, to peripheral blood T cells, but was absent from neoplastic T cells. Expression of TIMP-2 was shown to be restricted to cells of the T-cell lineage, with high levels observed in neoplastic T cells.41 This distinction might not be absolute because, in our experiments, cell lines also described as expressing some T-cell markers, such as the Holden and HDLM2 lines,51 were found to produce and secrete TIMP-1. Thus, our findings do not unequivocally support the hypothesis that H/R-S cells have a B-cell origin. In this context, it is interesting that elevated levels of TIMP-1 in TIMP-1 transgenic mice inhibit growth and metastasis of T-cell lymphoma.62 This effect, however, was thought to be not restricted to this histological type but to result from metalloproteinase inhibition by TIMPs and antiangiogenic properties of TIMPs. In accordance with studies describing cytokinelike activities of TIMPs
in a wide variety of cell types,32,42-48 Guedez et al49,50 observed that TIMP-1 was a survival factor for B
cells and induced differentiation in those cells. In our experiments assaying tritium-thymidine incorporation of H/R-S-derived cell lines,
neither TIMP-1 nor TIMP-1 antibodies produced a major modulation (Table
1). Thus, on the basis of our results, we cannot suggest a direct
cytokinelike role of TIMP-1 in the proliferation of H/R-S cells. We
also examined whether TIMP-1 affected radiation-induced and
H2O2-induced apoptosis and cell death. We found
that H/R-S-derived cell lines were extremely resistant to induction of
apoptosis, thus necessitating use of high doses of radiation and high
concentrations of H2O2. Several mechanisms
explaining the relative resistance to apoptosis of H/R-S cells have
been described in various studies,63-65 including
microarray studies64,65; these mechanisms include constitutive nuclear factor In HD, with the extensive infiltration of lymph nodes by cells of the
immunosurveillance system, immune-escape mechanisms are important in
explaining disease progression. Most lymphocytes in HD are
CD4+ and have a Th2 cytokine-production
profile.10 Several factors supporting this phenotype of
lymphocyte composition have been discussed.64 H/R-S cells
express several members of the TNF receptor family, such as the FAS
ligand (CD95L), that may induce apoptosis of activated FAS-positive,
CD8+ T cells and NK cells.10 Furthermore,
H/R-S cells produce TGF- The mechanisms leading to inhibition of T-cell cytotoxicity by TIMP-1
must be further elucidated. In addition to this inhibition by TIMP-1,
we found strong inhibition of T-cell cytotoxicity by TIMP-2 (Figure 9).
In this context, it is interesting that induction of apoptosis in
activated T-cells by TIMP-2 has been described.68 This was
not found when TIMP-2 fragments lacking the MMP binding domain were
used. Many cell-surface proteins are processed and shed by MMP-type
proteases, and down-regulation of FAS ligand by shedding has been
reported.69 Soluble FAS ligand inhibits cytotoxicity of
membrane-bound FAS ligand.69 Inhibition of
protease-induced soluble FAS ligand may explain induction of apoptosis
by TIMPs through a phenomenon described as fratricide.70
On the other hand, the cytotoxic lymphocyte serpin proteinase inhibitor
9 was shown to protect against granzyme B-mediated apoptosis without disturbing the FAS pathway,71 and this may be a mechanism
controlling misdirected fratricide apart from the FAS pathway.
Additional studies are needed to determine whether there is induction
of apoptosis of T-cells by TIMP-1 or interference between TIMP-1 and
granzyme B-mediated cytotoxicity in our experimental system. Interestingly, shedding inhibition of TNF- Viruses produce caspase inhibitors possibly to delay inflammatory processes and retard quick apoptosis of infected cells.73 One of these molecules, cytokine response modifier A, belongs to the serpin proteinase inhibitor family.73 It is interesting that a major retroviral gag core protein is structurally related to TIMP-174 and that Tax proteins of human T-cell leukemia viruses induce expression of TIMP-1.75 Additional studies of the relation between proteins of viruses important for HD development and protease inhibitors would be of great interest. Impaired specific T-cell cytotoxicity in HD testing targets, such as Epstein-Barr virus (EBV), has been observed in patients with EBV-positive HD.76,77 Our results provide an explanation for this phenomenon. However, aspects of immune escape in HD other than TIMP-1 might be important. Some could include cellular cooperation. It was reported that H/R-S cells produce a thymus and activation-regulated chemokine that is active in recruitment of CD4+ Th2 cells to be dominant in HD.10,78 CD4+ cells were found to inhibit CD8+ cytotoxic T-lymphocyte immunosurveillance against experimental tumors, including B-cell lymphomas.79,80 Immunotoxin depletion of regulatory cell populations producing immune-escape molecules such as IL-10 has been tested as a method for augmenting antitumor cytotoxic T cells.81 Additional studies of the use of this technique in HD, including the possible role of MMPs and TIMPs, would be interesting. Our ELISA analyses of plasma TIMP-1 levels in patients with different states of HD and in healthy controls revealed only a trend toward higher plasma levels in patients with DP, thus suggesting that the major role of TIMP-1 in HD is as an autocrine and paracrine molecule. This finding is somewhat in contrast to reports of comparatively high levels of TIMP-1 in blood samples from patients with advanced solid tumors.82 However, elevated IL-10 levels in the serum of patients with HD have been found to be associated with inferior disease-free survival.83 Thus, the prognostic importance of other immunomodulating molecules, including TIMP-1, in HD should be studied. Strategies for overcoming immune escape might be developed to improve the prognosis or increase the efficacy of immunotherapy. Finally, because TIMP-1 has direct effects on cells changing their phenotype,32,42-50 the existence of specific receptors can be postulated. However, only limited information on TIMP-1 binding sites is available. TIMP-2 binds to membrane type 1 metalloproteinase,84,85 as does TIMP-1, although with a lower affinity.86 Because integrins can interact with metalloproteinases,87 integrin signaling may play a role in these effects of TIMP-1 on cells. However, this and other possibilities require further study. In conclusion, this study showed that the proteinase inhibitor TIMP-1 is expressed by H/R-S cells in situ and in vitro. We also found that TIMP-1, besides having a role in the proteinase equilibrium, is an autocrine and paracrine survival factor for H/R-S cells and one of several immunosuppressive molecules expressed by H/R-S cells in situ and in vitro.
We thank U. Tank and G. Krull for technical assistance. Experiments were performed by E.O. as part of MD thesis.
Submitted July 26, 2000; accepted August 22, 2001.
Supported by a grant from Amgen-Germany.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Elisabeth Oelmann or Wolfgang E. Berdel, Department of Medicine (Hematology/Oncology), University Hospital, Westfaelische Wilhelms Universitaet Muenster, Albert-Schweitzer Street 33, D-48149, Muenster, Germany; e-mail: elisao{at}uni-muenster.de.
1.
Harris NL, Jaffe ES, Stein H, et al.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
Blood.
1994;84:1361-1392 2. Hsu SM, Waldron JW, Hsu PL, Hough AJ. Cytokines in malignant lymphomas. Human Pathol. 1993;24:1040-1057[CrossRef][Medline] [Order article via Infotrieve]. 3. Kaufman D, Longo DL. Hodgkin's disease. Crit Rev Oncol Hematol. 1992;13:135-187[Medline] [Order article via Infotrieve].
4.
Jücker M, Abts H, Li W, et al.
Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease.
Blood.
1991;77:2413-2418 5. Hsu SM, Zhao X. Expression of interleukin-1 in Reed-Sternberg cells and neoplastic cells from the true histiocytic malignancies. Am J Pathol. 1986;125:221-225[Abstract].
6.
Bargou RC, Mapara MY, Zugck C, et al.
Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.
J Exp Med.
1993;177:1257-1268 7. Foss HD, Herbst H, Oelmann E, et al. Lymphotoxin, tumor necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. Br J Haematol. 1993;84:627-635[Medline] [Order article via Infotrieve]. 8. Foss HD, Hummel M, Gottstein S, et al. Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease. Am J Pathol. 1995;146:33-39[Abstract].
9.
Jundt F, Anagnostopoulos I, Bommert K, et al.
Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils.
Blood.
1999;94:2065-2071 10. Poppema S, Potters M, Visser L, van den Berg AM. Immune escape mechanisms in Hodgkin's disease. Ann Oncol. 1998;9(suppl 5):S21-S24. 11. Docherty AJP, O'Connel J, Crabbe T, Angal S, Murphy G. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol. 1992;10:200-207[CrossRef][Medline] [Order article via Infotrieve]. 12. Matrisian LM. The matrix degrading metalloproteinases. Bioessays. 1992;14:455-463[CrossRef][Medline] [Order article via Infotrieve]. 13. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541-573[CrossRef]. 14. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999;103:1237-1241[Medline] [Order article via Infotrieve]. 15. DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol. 1997;425:89-97[Medline] [Order article via Infotrieve]. 16. Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol. 1997;183:377-379[CrossRef][Medline] [Order article via Infotrieve].
17.
Westermarck J, Kähäri VM.
Regulation of matrix metalloproteinase expression in tumor invasion.
FASEB J.
1999;13:781-792 18. Polette M, Birembaut P. Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol. 1998;30:1195-1202[CrossRef][Medline] [Order article via Infotrieve]. 19. Docherty AJP, Lyons A, Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 1985;318:66-69[CrossRef][Medline] [Order article via Infotrieve].
20.
Boone TC, Johnson MJ, DeClerck YA, Langley KE.
cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases.
Proc Natl Acad Sci U S A.
1990;87:2800-2804 21. Apte SS, Mattei MG, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics. 1994;19:86-90[CrossRef][Medline] [Order article via Infotrieve]. 22. Silbiger SM, Jacobsen VL, Cupples RL, Koski RA. Cloning of cDNAs encoding human TIMP-3, a novel member of the tissue inhibitor of metalloproteinase family. Gene. 1994;141:293-297[CrossRef][Medline] [Order article via Infotrieve].
23.
Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C.
Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family.
Cancer Res.
1994;54:2091-2094 24. Wilde CG, Hawkins PR, Coleman RT, et al. Cloning and characterization of human tissue inhibitor of metalloproteinase-3. DNA Cell Biol. 1994;13:711-718[Medline] [Order article via Infotrieve].
25.
Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE.
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4.
J Biol Chem.
1996;271:30375-30380 26. Tuuttila A, Morgunova E, Bergmann U, et al. Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution. J Mol Biol. 1998;284:1133-1140[CrossRef][Medline] [Order article via Infotrieve]. 27. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 1999;55:639-652[CrossRef][Medline] [Order article via Infotrieve]. 28. Gomis-Rüth FX, Maskos K, Betz M, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997;389:77-81[CrossRef][Medline] [Order article via Infotrieve]. 29. Fabunmi RP, Baker AH, Murray EJ, Booth RFG, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335-342.
30.
Roeb E, Graeve L, Müllberg J, Matern S, Rose-John S.
TIMP-1 protein expression is stimulated by IL-1 31. Nemoto O, Yamada H, Mukaida M, Shimmei M. Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Arthritis Rheum. 1996;39:560-566[Medline] [Order article via Infotrieve].
32.
Lotz M, Guerne PA.
Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA).
J Biol Chem.
1991;266:2017-2020 33. Hosono T, Ito A, Sato T, Nagase H, Mori Y. Translational augmentation of pro-matrix metalloproteinase 3 (prostromelysin 1) and tissue inhibitor of metalloproteinases (TIMP)-1 mRNAs induced by epidermal growth factor in human uterine cervical fibroblasts. FEBS Lett. 1996;381:115-118[CrossRef][Medline] [Order article via Infotrieve]. 34. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995;96:2304-2310. 35. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol. 1993;94:145-149[Medline] [Order article via Infotrieve]. 36. Roeb E, Graeve L, Hoffmann R, Decker K, Edwards DR, Heinrich PC. Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology. 1993;18:1437-1442[CrossRef][Medline] [Order article via Infotrieve]. 37. Johnatty RN, Taub DD, Reeder SP, et al. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol. 1997;158:2327-2333[Abstract].
38.
Borland G, Murphy G, Ager A.
Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes.
J Biol Chem.
1999;274:2810-2815
39.
Kossakowska AE, Urbanski SJ, Edwards DR.
Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas.
Blood.
1991;77:2475-2481
40.
Kossakowska AE, Edwards DR, Prusinkiewicz C, et al.
Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas.
Blood.
1999;94:2080-2089
41.
Stetler-Stevenson M, Mansoor A, Lim M, et al.
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells.
Blood.
1997;89:1708-1715 42. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS Lett. 1992;298:29-32[CrossRef][Medline] [Order article via Infotrieve]. 43. Bertaux B, Hornebeck W, Eisen AZ, Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol. 1991;97:679-685[CrossRef][Medline] [Order article via Infotrieve]. 44. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci. 1994;107:2373-2379[Abstract].
45.
Chesler L, Golde DW, Bersch N, Johnson MD.
Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1.
Blood.
1995;86:4506-4515
46.
Corcoran ML, Stetler-Stevenson WG.
Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism.
J Biol Chem.
1995;270:13453-13459
47.
Avalos BR, Kaufman SE, Tomonaga M, Williams RE, Golde DW, Gasson JC.
K562 cells produce and respond to human erythroid-potentiating activity.
Blood.
1988;71:1720-1725 48. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. J Clin Invest. 1998;101:1478-1487[Medline] [Order article via Infotrieve]. 49. Guedez L, Stetler-Stevenson WG, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998;102:2002-2010[Medline] [Order article via Infotrieve].
50.
Guedez L, Courtemanch L, Stetler-Stevenson M.
Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells.
Blood.
1998;92:1342-1349 51. Drexler H. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma. 1993;9:1-25[Medline] [Order article via Infotrieve].
52.
Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA.
Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues.
J Biol Chem.
1990;265:13933-13938 53. Milani S, Herbst H, Schuppan D, et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol. 1994;144:528-537[Abstract]. 54. Herbst H, Heinrichs O, Schuppan D, Milani S, Stein H. Temporal and spatial patterns of transin/stromelysin RNA expression following toxic injury in rat liver. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60:295-300[Medline] [Order article via Infotrieve].
55.
Herbst H, Steinbrecher T, Niedobitek G, et al.
Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease.
Blood.
1992;80:484-491 56. Milani S, Herbst H, Schuppan D, Hahn EG, Stein H. In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver. Evidence for predominant expression in nonparenchymal liver cells. Hepatology. 1989;10:84-92[Medline] [Order article via Infotrieve]. 57. Williamson DJ. Specificity of riboprobes for intracellular RNA in hybridization histochemistry. J Histochem Cytochem. 1988;36:811-813[Abstract].
58.
Kägi D, Vignaux F, Ledermann B, Bürki K, et al.
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.
Science.
1994;265:528-530 59. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and fas lytic pathways. Nature. 1994;370:650-652[CrossRef][Medline] [Order article via Infotrieve]. 60. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157:2539-2548[Abstract]. 61. Brown DM, Phipps RP. Bcl-2 expression inhibits prostaglandin E2-mediated apoptosis in B cell lymphomas. J Immunol. 1996;157:1359-1370[Abstract].
62.
Krüger A, Fata JE, Khokha R.
Altered tumor growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice.
Blood.
1997;90:1993-2000
63.
Bargou RC, Emmerich F, Krappmann D, et al.
Constitutive nuclear factor-
64.
Staudt LM.
The molecular and cellular origins of Hodgkin's disease.
J Exp Med.
2000;191:207-212
65.
Hinz M, Löser P, Mathas S, Krappmann D, Dörken B, Scheidereit C.
Constitutive NF- 66. Kägi D, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol. 1996;14:207-232[CrossRef][Medline] [Order article via Infotrieve].
67.
Maggi E, Parronchi P, Macchia D, Bellesi G, Romagnani S.
High numbers of CD4+ T cells showing abnormal recognition of DR antigens in lymphoid organs involved by Hodgkin's disease.
Blood.
1988;71:1503-1506 68. Lim MS, Guedez L, Stetler-Stevenson WG, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes. Ann N Y Acad Sci 1999;878:522-523[CrossRef][Medline] [Order article via Infotrieve]. 69. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of FAS ligand by shedding. Nature Med. 1998;4:31-36[CrossRef][Medline] [Order article via Infotrieve]. 70. Vignaux F, Goldstein P. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway? Eur J Immunol. 1994;24:923-927[Medline] [Order article via Infotrieve].
71.
Bird CH, Sutton VR, Sun J, et al.
Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway.
Mol Cell Biol.
1998;18:6387-6398
72.
Lombard MA, Wallace TL, Kubicek MF, et al.
Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-
73.
Ray CA, Black RA, Kronheim SR, et al.
Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 74. Patarca R, Haseltine WR. A major retroviral core protein related to EPA and TIMP. Nature. 1985;318:390[CrossRef][Medline] [Order article via Infotrieve].
75.
Uchijima M, Sato H, Fujii M, Seiki M.
Tax proteins of human T-cell leukemia virus type 1 and 2 induce expression of the gene encoding erythroid-potentiating activity (tissue inhibitor of metalloproteinase-1, TIMP-1).
J Biol Chem.
1994;269:14946-14950
76.
Frisan T, Sjöberg J, Dolcetti R, et al.
Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease.
Blood.
1995;86:1493-1501
77.
Sing AP, Ambinder RF, Hong DJ, et al.
Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.
Blood.
1997;89:1978-1986
78.
Van den Berg A, Visser L, Poppema S.
High expression of the CC chemokine TARC in Reed-Sternberg cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma.
Am J Pathol.
1999;154:1685-1691 79. Ohnishi K, Bonavida B. Regulation of B-cell lymphoma growth in syngeneic SJL/J mice. Establishment of tumor dormancy following administration of anti-CD4 monoclonal antibody into tumor-bearing mice. Leukemia. 1993;7:1801-1806[Medline] [Order article via Infotrieve].
80.
Matsui S, Ahlers JD, Vortmeyer AO, et al.
A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
J Immunol.
1999;163:184-193
81.
Seo N, Tokura Y, Takigawa M, Egawa K.
Depletion of IL-10- and TGF- 82. Holten-Andersen MN, Murphy G, Nielsen HJ, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer. 1999;80:495-503[CrossRef][Medline] [Order article via Infotrieve].
83.
Sarris AH, Kliche K-O, Pethambaram P, et al.
Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.
Ann Oncol.
1999;10:433-440
84.
Butler GS, Butler MJ, Atkinson SJ, et al.
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study.
J Biol Chem.
1998;273:871-880
85.
Zucker S, Drews M, Conner C, et al.
Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP).
J Biol Chem.
1998;273:1216-1222 86. Fernandez-Catalan C, Bode W, Huber R, et al. Crystal structure of the complex formed by the membrane type 1 matrix metalloproteinase with the tissue inhibitor of metalloproteinase-2, the soluble progelatinase A receptor. EMBO J. 1998;17:5238-5248[CrossRef][Medline] [Order article via Infotrieve]. 87. Brooks PC, Siletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 1998;92:391-400[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. Sanchez-Espiridion, A. Sanchez-Aguilera, C. Montalban, C. Martin, R. Martinez, J. Gonzalez-Carrero, C. Poderos, C. Bellas, M. F. Fresno, C. Morante, et al. A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples Clin. Cancer Res., February 15, 2009; 15(4): 1367 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jiang, H. Zhu, X. Chen, Y. Peng, J. Wang, F. Liu, S. Shi, B. Fu, Y. Lu, Q. Hong, et al. TIMP-1 Transgenic Mice Recover From Diabetes Induced by Multiple Low-Dose Streptozotocin Diabetes, January 1, 2007; 56(1): 49 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Verstappen and J.W. Von den Hoff Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease Journal of Dental Research, December 1, 2006; 85(12): 1074 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Re, R. Kuppers, and V. Diehl Molecular Pathogenesis of Hodgkin's Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6379 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Guedez, A. Martinez, S. Zhao, A. Vivero, S. Pittaluga, M. Stetler-Stevenson, M. Raffeld, and W. G. Stetler-Stevenson Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors Blood, February 15, 2005; 105(4): 1660 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamazaki, T. Akahane, T. Buck, H. Yoshiji, D. E. Gomez, D. J. Schoeffner, E. Okajima, S. R. Harris, O. R. Bunce, S. S. Thorgeirsson, et al. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice Carcinogenesis, September 1, 2004; 25(9): 1735 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kong, R. Poon, P. Nadesan, T. Di Muccio, R. Fodde, R. Khokha, and B. A. Alman Matrix Metalloproteinase Activity Modulates Tumor Size, Cell Motility, and Cell Invasiveness in Murine Aggressive Fibromatosis Cancer Res., August 15, 2004; 64(16): 5795 - 5803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lai, G. Z. Rassidakis, L. J. Medeiros, L. Ramdas, A. H. Goy, C. Cutler, Y. Fujio, K. Kunisada, H. M. Amin, and F. Gilles Signal Transducer and Activator of Transcription-3 Activation Contributes to High Tissue Inhibitor of Metalloproteinase-1 Expression in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma Am. J. Pathol., June 1, 2004; 164(6): 2251 - 2258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Savage, S. Monti, J. L. Kutok, G. Cattoretti, D. Neuberg, L. de Leval, P. Kurtin, P. D. Cin, C. Ladd, F. Feuerhake, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma Blood, December 1, 2003; 102(12): 3871 - 3879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.A. Young, J.D. Hennebold, and R.L. Stouffer Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle Mol. Hum. Reprod., September 1, 2002; 8(9): 833 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Baker, D. R. Edwards, and G. Murphy Metalloproteinase inhibitors: biological actions and therapeutic opportunities J. Cell Sci., January 10, 2002; 115(19): 3719 - 3727. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, tumor necrosis factor (TNF)-
(TGF-
B activation
T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
J Immunol.
1999;163:242-249